We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Dr Sophie Kellaway at the University of Nottingham is investigating whether an asthma drug could help provide a new, targeted treatment for acute myeloid leukaemia.
Dr Katrina Lappin at Queen's University Belfast aims to create a cost effective and more accurate acute myeloid leukaemia model to test treatments on.
Dr Matthew Blunt aims to create and test immunotherapy treatments for rhabdomyosarcoma that are safer and more effective than chemotherapy.
Dr Maarten Hoogenkamp will continue his work into blocking the EAAT1 protein, which is crucial for the growth of T-cell acute lymphoblastic leukaemia.
Professor Shivaram Avula will identify markers in the brains of young people with brain tumours that will help predict the development of long-term side effects like learning and memory problems.
Dr Karen Keeshan is researching to see if removing or blocking a specific protein involved in acute myeloid leukaemia can help make it easier to treat.
Dr Samanta Mariani and her team want to understand more about the role immune cells play to help develop new ways to treat leukaemia in babies.
Professor Rylie Green at Imperial College London will test a device that can deliver chemotherapy directly to brain tumours, sparing healthy cells.
Dr Ashley Vardon at the University of Birmingham hopes to find a way to effectively fight diffuse midline glioma with new immunotherapies.
